Cellectar Biosciences Inc (NASDAQ:CLRB)

2.00
Delayed Data
As of 3:59pm ET
 +0.09 / +4.71%
Today’s Change
1.01
Today|||52-Week Range
2.98
-3.85%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$84.1M

Company Description

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Contact Information

Cellectar BioSciences, Inc.
100 Campus Drive
Florham Park New Jersey 07932
P:(608) 441-8120
Investor Relations:

Employees

Shareholders

Other institutional40.03%
Mutual fund holders3.66%
Individual stakeholders0.48%

Top Executives

James V. CarusoPresident, Chief Executive Officer & Director
Dov S. ElefantChief Financial Officer & Vice President
John E. FriendChief Medical Officer & Vice President
Jarrod LongcorChief Business Officer
Gregory J. LynchSecretary